Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
9.28
-1.07 (-10.34%)
At close: Feb 21, 2025, 4:00 PM
9.27
-0.01 (-0.11%)
After-hours: Feb 21, 2025, 7:59 PM EST
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $26.08M in the quarter ending September 30, 2024, with 147.62% growth. This brings the company's revenue in the last twelve months to $65.18M, up 37.64% year-over-year. In the year 2023, Recursion Pharmaceuticals had annual revenue of $44.58M with 11.88% growth.
Revenue (ttm)
$65.18M
Revenue Growth
+37.64%
P/S Ratio
34.97
Revenue / Employee
$130,368
Employees
500
Market Cap
3.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
Dec 31, 2019 | 2.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RXRX News
- 4 days ago - Altitude Lab Startups Raise $154M in Capital - GlobeNewsWire
- 8 days ago - Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off - Seeking Alpha
- 16 days ago - Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference - GlobeNewsWire
- 6 weeks ago - Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More - GlobeNewsWire
- 6 weeks ago - Recursion to Present at 43rd Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 2 months ago - Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha
- 2 months ago - Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability - GlobeNewsWire